Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Translated into:
Welcome To Welox Pharma WHO-GMP | ISO 9001:2015
Introduction to Olumiant (Baricitinib) 4 mg
Olumiant, with the active ingredient Baricitinib, is a targeted therapy designed to treat autoimmune conditions by inhibiting specific enzymes involved in the inflammatory process. It is specifically approved for use in adults with moderate to severe rheumatoid arthritis.
Uses of Olumiant (Baricitinib) 4 mg
Rheumatoid Arthritis: Effective in reducing signs and symptoms in adult patients with moderate to severe rheumatoid arthritis, especially in those who have not responded well to other treatments.
COVID-19 Treatment (Emergency Use): In certain cases, Olumiant has been authorized for emergency use in treating COVID-19 in hospitalized adults, in combination with other treatments, to manage severe disease symptoms.
Benefits of Olumiant (Baricitinib) 4 mg
Reduced Inflammation: Helps decrease joint pain, swelling, and stiffness by targeting specific pathways involved in the inflammatory process.
Slowed Disease Progression: Slows down the progression of joint damage, preserving joint function and mobility.
Improved Physical Function: Enhances daily functioning and overall quality of life by alleviating symptoms of rheumatoid arthritis.
Oral Administration: Convenient oral tablet form, making it easier for patients to maintain adherence to their treatment regimen.
Targeted Therapy: Specifically inhibits Janus kinase enzymes, providing a more focused treatment approach with potentially fewer systemic side effects compared to broader immunosuppressive therapies.
Mechanism of Action of Olumiant (Baricitinib) 4 mg
Baricitinib: The active compound, Baricitinib, is a selective inhibitor of Janus kinase (JAK) enzymes, particularly JAK1 and JAK2. These enzymes are crucial in the signaling pathways of pro-inflammatory cytokines that are involved in the immune response.